Our Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS PF) Minimal Disease Activity (MDA), a tool developed at Johns Hopkins and validated within our PsA cohort, allows for exquisite description of […]
In 2015, Johns Hopkins scientists proved that scleroderma is often a casualty of war: it is the unfortunate consequence of the body’s battle to fight off cancer. We have since […]
The vast majority of the patients who take statins don’t ever have to worry about the side effect of muscle symptoms. Even among those who do experience muscle damage, with […]
A prevalent belief among rheumatologists has been that an accurate diagnosis of Sjögren’s is not essential because of the lack of disease-modifying therapies. But a correct diagnosis is very important […]
Corticosteroids (prednisone) are the mainstay of therapy for systemic lupus erythematosus (SLE). Prednisone works: it has anti-inflammatory and immunosuppressive actions in SLE. This is why doctors who treat lupus patients […]
The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 […]
